3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Head and Neck Neoplasms
1
Head and Neck Carcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
17
Nivolumab
6
Docetaxel
6
Gemcitabine
5
Cisplatin
5
Carboplatin
5
durvalumab
4
Paclitaxel
4
Ipilimumab
4
avelumab
3
atezolizumab
3
Filgrastim
3
Cyclophosphamide
3
Bortezomib
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
tislelizumab
2
spartalizumab
2
fludarabine
2
epacadostat
2
enzalutamide
2
aldesleukin
2
abiraterone
2
Radiotherapy
2
Psychiatric Rehabilitation
2
Polymerase Chain Reaction
2
Nicotine
2
Irinotecan
2
Interleukin-2
2
Injections
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Solutions
×
Head & Neck
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled